You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

Drug Sales Trends for DAYTRANA


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for DAYTRANA (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
INSIDE ANOTHER STORE $8,544,916
INSIDE HMO/CLINIC/HOSPITAL $1,603,779
[disabled in preview] $107,260,870
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
INSIDE ANOTHER STORE 21,392
INSIDE HMO/CLINIC/HOSPITAL 4,015
[disabled in preview] 268,521
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $1,603,779
PRIVATE INSURANCE $104,282,967
[disabled in preview] $11,522,818
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for DAYTRANA
Drug Units Sold Trends for DAYTRANA

Annual Sales Revenues and Units Sold for DAYTRANA

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
DAYTRANA ⤷  Try for Free ⤷  Try for Free 2021
DAYTRANA ⤷  Try for Free ⤷  Try for Free 2020
DAYTRANA ⤷  Try for Free ⤷  Try for Free 2019
DAYTRANA ⤷  Try for Free ⤷  Try for Free 2018
DAYTRANA ⤷  Try for Free ⤷  Try for Free 2017
DAYTRANA ⤷  Try for Free ⤷  Try for Free 2016
>Drug Name >Revenues (USD) >Units >Year

Market Analysis and Sales Projections for DAYTRANA

Introduction to DAYTRANA

DAYTRANA, developed and manufactured by Noven Pharmaceuticals, is the first and only transdermal medication approved by the FDA to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years. It contains the active ingredient methylphenidate, delivered through a transdermal patch[1].

Historical Sales Performance

Since its approval, DAYTRANA has shown significant sales growth. By the end of July 2007, Shire's net sales of DAYTRANA exceeded $50 million in the preceding 12 months, triggering a $25 million milestone payment to Noven. In the year leading up to this milestone, DAYTRANA sales to Shire totaled $8.6 million, with $5.9 million recognized in related license revenues. An estimated 700,000 patches were sold during this period[1].

Market Impact and Competition

The ADHD market is highly competitive, with various drug types and formulations available. DAYTRANA's unique transdermal delivery system sets it apart, but it faces competition from other popular ADHD medications like Vyvanse. The launch of Vyvanse, for example, negatively impacted the volume of U.S. prescriptions for DAYTRANA, although DAYTRANA's revenues still increased by 71% year-over-year due to price increases and lower sales deductions[3].

Patent and Generic Landscape

DAYTRANA is protected by three U.S. patents and one international patent family member. However, a generic version of DAYTRANA, also containing methylphenidate, was approved by Mylan (now Viatris) on March 14, 2022. This development is likely to impact DAYTRANA's sales as generic alternatives become more available and potentially more cost-effective for consumers[4].

Current Market Trends

The ADHD market as a whole is experiencing mixed trends. Globally, the market size was estimated at $15.8 billion in 2023 and is projected to reach $24.6 billion by 2032, growing at a CAGR of 5.1% during the forecast period. However, in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), the ADHD market is forecast to decline at a negative CAGR of 0.9% from $11.9 billion in 2022 to $10.9 billion in 2032. This decline is driven by patent expiries and the anticipated launch of generic products[2][5].

Sales Projections

Given the approval of generic versions and the competitive landscape, DAYTRANA's sales are likely to face significant challenges. Here are some key points to consider:

  • Generic Competition: The approval of a generic version of DAYTRANA in 2022 is expected to erode the market share of the branded product. Generic launches typically lead to a reduction in sales for branded products as payers and consumers opt for the more cost-effective generic alternatives[4][5].
  • Market Decline: The overall ADHD market in the 7MM is expected to decline due to patent expiries and generic launches. This broader market trend will likely impact DAYTRANA's sales negatively[5].
  • Historical Growth: Despite the challenges, DAYTRANA has historically shown strong growth, particularly in its early years. However, this growth is unlikely to be sustained in the face of increasing generic competition[1].

Future Outlook

The future outlook for DAYTRANA is complex:

  • Generic Uptake: The uptake of generic methylphenidate patches is expected to increase, especially as API shortages affecting the ADHD market are resolved by 2027. This will likely result in significant sales erosion for DAYTRANA[5].
  • Pricing and Market Share: As generic products become more prevalent, DAYTRANA's market share and pricing power are expected to diminish. This could lead to a decline in revenues and profitability for the product[5].

Key Takeaways

  • DAYTRANA is a unique transdermal medication for ADHD but faces intense competition and generic challenges.
  • The approval of generic versions of DAYTRANA is expected to significantly impact its sales.
  • The broader ADHD market trends, including patent expiries and generic launches, will also affect DAYTRANA's sales projections.
  • Despite historical growth, DAYTRANA's future sales are likely to decline due to these factors.

FAQs

Q: What is DAYTRANA, and how is it administered? A: DAYTRANA is a transdermal patch containing methylphenidate, used to treat ADHD symptoms in children aged 6 to 12 years.

Q: What were the historical sales figures for DAYTRANA? A: By the end of July 2007, DAYTRANA's net sales exceeded $50 million in the preceding 12 months, triggering a $25 million milestone payment to Noven.

Q: How does the generic approval impact DAYTRANA's sales? A: The approval of a generic version of DAYTRANA in 2022 is expected to erode the market share and sales of the branded product as consumers opt for the more cost-effective generic alternative.

Q: What are the broader market trends affecting DAYTRANA? A: The ADHD market in the 7MM is forecast to decline due to patent expiries and generic launches, which will negatively impact DAYTRANA's sales.

Q: When are the patents for DAYTRANA expected to expire? A: DAYTRANA is protected by three U.S. patents, but specific expiration dates are not provided in the available sources. However, the generic approval indicates that key patents may have expired or are nearing expiration.

Sources

  1. Outsourcing-Pharma.com - ADHD transdermal patches withdrawn
  2. GMINsights.com - Attention Deficit Hyperactivity Disorder Market Share, 2024-2032
  3. SPGlobal.com - Shire Posts 37% Increase in Pharmaceutical Sales During Q1
  4. DrugPatentWatch.com - When do the patents on DAYTRANA expire, and when will generic versions be available?
  5. ClinicalTrialsArena.com - 7MM ADHD market forecast to decline by $1bn between 2022 and 2032
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.